FibroBiologics (NASDAQ:FBLG) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research report report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $15.00 target price on the stock.

FBLG has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of FibroBiologics in a report on Friday, September 12th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

FibroBiologics Stock Up 0.3%

FibroBiologics stock opened at $0.39 on Monday. FibroBiologics has a 52 week low of $0.38 and a 52 week high of $3.89. The company’s 50 day moving average price is $0.51 and its two-hundred day moving average price is $0.68. The stock has a market cap of $16.53 million, a P/E ratio of -0.82 and a beta of -0.71.

FibroBiologics (NASDAQ:FBLG) last posted its earnings results on Friday, October 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.03). On average, equities analysts anticipate that FibroBiologics will post -0.53 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in FBLG. Cerity Partners LLC grew its position in shares of FibroBiologics by 19.6% during the 1st quarter. Cerity Partners LLC now owns 93,407 shares of the company’s stock valued at $84,000 after purchasing an additional 15,306 shares in the last quarter. Nuveen LLC purchased a new position in shares of FibroBiologics during the 1st quarter valued at $31,000. AQR Capital Management LLC purchased a new position in shares of FibroBiologics during the 1st quarter valued at $29,000. Y Intercept Hong Kong Ltd purchased a new position in shares of FibroBiologics during the 2nd quarter valued at $37,000. Finally, Ethos Financial Group LLC grew its position in shares of FibroBiologics by 100.0% during the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock valued at $30,000 after purchasing an additional 24,424 shares in the last quarter.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.